These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20868323)

  • 21. Regenerative medicine. The industry comes of age.
    Mason C
    Med Device Technol; 2007; 18(2):25-30. PubMed ID: 17494498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Commercial development of cell-based therapeutics: strategic considerations along the drug to tissue spectrum.
    Parenteau NL
    Regen Med; 2009 Jul; 4(4):601-11. PubMed ID: 19580408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. India changes patent law to meet WTO treaty, making new medicines less available to most citizens, other countries.
    James JS
    AIDS Treat News; 2004; (407-408):6-7. PubMed ID: 15717384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 'The Little Purple Book': BSI glossary of regenerative medicine. Foreword.
    Mason C; Manzotti E
    Regen Med; 2009 Jul; 4(4):483-4. PubMed ID: 19580396
    [No Abstract]   [Full Text] [Related]  

  • 25. The challenges of product development and commercialization in a convergence technology world: focus on regenerative medicine.
    Tozer D
    Drug Discov Today; 2010 Aug; 15(15-16):587-9. PubMed ID: 20546921
    [No Abstract]   [Full Text] [Related]  

  • 26. From Bilski back to Benson: preemption, inventing around, and the case of genetic diagnostics.
    Dreyfuss R; Evans JP
    Stanford Law Rev; 2011 Jun; 63(6):1349-76. PubMed ID: 21774194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Communicating the needs of businesses to patent analysts.
    Simmons ES
    Pharm Pat Anal; 2012 Nov; 1(5):509-11. PubMed ID: 24236916
    [No Abstract]   [Full Text] [Related]  

  • 28. Catalyzing stem cell research.
    Willemse L; Lyall D; Rudnicki M
    Regen Med; 2008 Sep; 3(5):761-4. PubMed ID: 18729799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New glossary of terms used in regenerative medicine: standardization continues to emerge as regenerative medicine matures.
    Sheridan B; Harris N
    Regen Med; 2009 Jul; 4(4):621-2. PubMed ID: 19580410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Upcoming challenges in intellectual property presented by emerging pharmaceutical technologies.
    Komatani TS
    Pharm Pat Anal; 2017 Jan; 6(1):1-4. PubMed ID: 28198642
    [No Abstract]   [Full Text] [Related]  

  • 31. Pearl 30th anniversary: nanotechnology & regenerative medicine.
    Tan A; Seifalian AM
    Biotechnol Adv; 2013; 31(5):490. PubMed ID: 23790520
    [No Abstract]   [Full Text] [Related]  

  • 32. Science and the law. Patent swords and shields.
    Eisenberg RS
    Science; 2003 Feb; 299(5609):1018-9. PubMed ID: 12586927
    [No Abstract]   [Full Text] [Related]  

  • 33. Patents discipline is key to securing big pharma investment.
    Jones N
    Drug Discov Today; 2012 Jan; 17(1-2):1-2. PubMed ID: 22138380
    [No Abstract]   [Full Text] [Related]  

  • 34. Intellectual property. What good is a patent? Supreme Court may suggest an answer.
    Kintisch E
    Science; 2006 Feb; 311(5763):946-7. PubMed ID: 16484470
    [No Abstract]   [Full Text] [Related]  

  • 35. Canadian Journal of Cardiology in 2014: from percutaneous intervention to regenerative medicine.
    Nattel S
    Can J Cardiol; 2014 Jan; 30(1):1-2. PubMed ID: 24365187
    [No Abstract]   [Full Text] [Related]  

  • 36. World Trade Organization debates patent rights for drugs.
    AIDS Policy Law; 2001 Nov; 16(21):2. PubMed ID: 11769182
    [No Abstract]   [Full Text] [Related]  

  • 37. Patent pending. The challenges of bringing an invention to market.
    Goldman PM
    Minn Med; 1999 Sep; 82(9):29-31. PubMed ID: 10510615
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug development. Corruption and research fraud send big chill through big pharma in China.
    Hvistendahl M
    Science; 2013 Aug; 341(6145):445-6. PubMed ID: 23908198
    [No Abstract]   [Full Text] [Related]  

  • 39. Big business eyes medical issues. Interview by James D. Snyder.
    Goldbeck WB
    Va Med; 1980 Mar; 107(3):172-5. PubMed ID: 6767312
    [No Abstract]   [Full Text] [Related]  

  • 40. The strong financial case for regenerative medicine and the regen industry.
    Mason C; Dunnill P
    Regen Med; 2008 May; 3(3):351-63. PubMed ID: 18462058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.